Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings
New York, Jan 14, 2026, 18:15 EST — After-hours Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli. Investors are zeroing in on Johnson & Johnson’s drug pipeline for the next growth phase as the company gears up for its quarterly report next week. Oncology…